一、概述 赖氨酸（Lysine），简称为Lys，是一种α-氨基酸，化学名称2,6-二氨基己酸，是许多蛋白质的前体，它 包含一个α-氨基(在生物学条件下为质子化- NH3+形式)、一个α-羧酸基(在生物学条件下为去质子化- COO -形式)和一个侧链赖氨酸((CH2)4NH2)，将其分类为碱性带电(在生理pH值下)脂肪族氨基酸，是人 体必需氨基酸之一。 赖氨酸人体自身无法合成，必须通过食物/营养补充剂获取，其核心生理作用是参与蛋白质合成、促进 生长发育、修复组织；辅助合成胶原蛋白、肉碱、激素与酶；提升钙吸收、改善免疫功能、参与脂肪代 谢。按旋光异构与生物活性不同，赖氨酸可以分为L-赖氨酸（L-Lysine）和D-赖氨酸（D-Lysine）；按 来源不同，赖氨酸可以分为天然来源赖氨酸和合成/发酵来源赖氨酸。 赖氨酸分类 二、市场政策 我国高度重视包括赖氨酸在内的氨基酸产业发展，相继发布《中华人民共和国国民经济和社会发展第十 四个五年规划和2035年远景目标纲要》《推动原料药产业高质量发展实施方案的通知》《"十四五"生物 经济发展规划》《关于印发中原农谷发展规划（2022—2035年）的通知》《关于特殊膳食用食品中 ...

内容概要：随着生猪养殖、家禽养殖、水产养殖规模化、集约化程度持续提升，配合饲料市场渗透率不 断提高，蛋氨酸作为畜禽水产生长发育的必需氨基酸，是饲料配方中不可替代的核心添加剂，饲料领域 市场需求随之稳步攀升，与此同时，蛋氨酸在食品营养强化、医药氨基酸输液、保健品、日化原料等非 饲料领域的应用场景持续拓宽，非饲料端需求快速增长，打破行业长期单一依赖养殖产业的格局，多元 需求结构逐步形成，不仅有效平抑行业周期性波动风险，更为产业发展打开全新增长空间，据统计， 2025年我国蛋氨酸需求量达40.9万吨，同比增长3.6%；全年产量完成54.6万吨，同比增长10.3%。 上市企业：新和成（002001）、和邦生物（603077）、安迪苏（600299） 相关企业：赢创（中国）投资有限公司、住友化学（上海）有限公司、希杰（中国）咨询有限公司、宁 夏紫光天化蛋氨酸有限责任公司、河北华阳生物科技有限公司 关键词：蛋氨酸行业相关政策汇总、蛋氨酸产业链图谱、蛋氨酸供需现状、蛋氨酸进出口贸易、蛋氨酸 竞争格局、蛋氨酸发展趋势 一、概述 蛋氨酸，学名甲硫氨酸（Methionine，缩写Met/M），是含硫的必需氨基酸，人体及动物自身无 ...

Group 1 - The company is integrating its acquired overseas business according to its established plan, with specific performance details available in regular reports [1] - The acquired assets primarily consist of pharmaceutical amino acid products, including arginine and histidine, for which domestic production bases have initiated project preparations [1]

Group 1 - The core point of the news is that Huaheng Biological experienced a decline of 5.22% in its stock price, reaching 37.80 CNY per share, with a trading volume of 464 million CNY and a turnover rate of 4.77%, resulting in a total market capitalization of 9.454 billion CNY [1] - Huaheng Biological, established on April 13, 2005, and listed on April 22, 2021, is primarily engaged in the research, production, and sales of amino acids and their derivatives, with the main revenue composition being 70.96% from amino acid series, 20.96% from other supplements, 5.34% from vitamins, and 2.74% from other products [1] Group 2 - From the perspective of major circulating shareholders, the fund under Jiao Yin Schroder has reduced its holdings in Huaheng Biological by 3.8368 million shares, now holding 4.3135 million shares, which accounts for 1.72% of the circulating shares, resulting in an estimated floating loss of approximately 8.9721 million CNY [2] - The Jiao Yin Advanced Manufacturing Mixed A fund, managed by Guo Ruo, has a total asset scale of 4.497 billion CNY, with a year-to-date return of 3.32% and a one-year return of 55.55% [2][3] Group 3 - The Jiao Yin Advanced Manufacturing Mixed A fund has Huaheng Biological as its seventh-largest heavy stock, with the reduced holdings accounting for 3.05% of the fund's net value, leading to an estimated floating loss of about 8.9721 million CNY [4]

Core Viewpoint - Huaheng Biological has submitted a listing application to the Hong Kong Stock Exchange for an "A+H" dual listing, with Huatai International as the sole sponsor. The company specializes in the research, production, and sales of bio-based products, holding the largest global market share for L-alanine and L-valine as of 2024. However, it faces significant challenges including declining product prices, sharply reduced profit margins, and intensified industry competition [1][2]. Financial Performance - From 2022 to 2024, Huaheng Biological's revenue is projected to grow from 1.419 billion to 2.178 billion yuan, indicating a strong growth trend. However, net profit is expected to drop from 319 million yuan in 2022 to 185 million yuan in 2024, reflecting a year-on-year decline of 58.67%. In the first three quarters of 2025, revenue reached 2.194 billion yuan, a year-on-year increase of 42.53%, but net profit still fell by 5.1% to 159 million yuan [2][3]. - The company's gross margin has significantly decreased from 40.4% in 2023 to 24.8% in 2024, and further down to 23.5% in the first three quarters of 2025, nearly halving from its peak [2][3]. Product Pricing and Market Dynamics - The decline in profitability is attributed to a comprehensive drop in market prices across nearly all product lines. For instance, the average price of amino acid products has fallen from 18,900 yuan per ton in 2022 to 15,000 yuan per ton in the first half of 2025, a decrease of over 20%. Specifically, the price of L-alanine dropped from 35,000 yuan per ton at the beginning of 2025 to 20,000 yuan per ton by mid-year, a decline of approximately 42.86% [3][4]. Supply and Demand Changes - The market's supply-demand dynamics have shifted significantly, with many sub-markets transitioning from high growth to stagnation. For example, the compound annual growth rate for valine is expected to drop from 60.2% (2020-2024) to 8.6% (2024-2030) and further to 3.4% (2030-2035). The inositol market is projected to experience nearly stagnant growth during the same period [4][5]. - The oversupply situation is exacerbated by rapid capacity expansion driven by high previous profits, alongside a slowdown in downstream demand due to macroeconomic factors. This has led to increased price competition [4][5]. Industry Competition and Strategic Shifts - Other companies in the industry are also expanding capacity, with significant new production planned for L-valine by competitors such as Yipin Biological and Jinhai Biological, which will further intensify competition [5][6]. - In response to the fierce competition in its core business, Huaheng Biological is attempting to pivot towards high-value beauty and personal care ingredients. However, this transition faces challenges due to the importance of patent barriers, brand effects, and channel control, areas where the company currently lacks strength [6][7].

Investment Rating - The investment rating for the company is "Buy" with a target price of RMB 12.70 [1][4]. Core Views - The company reported Q3 revenue of RMB 5.9 billion, a year-over-year decrease of 2% and a quarter-over-quarter decrease of 1%. However, the net profit attributable to the parent company was RMB 1.26 billion, showing a year-over-year increase of 141% and a quarter-over-quarter increase of 68% [1]. - The company’s net profit for the first three quarters of 2025 reached RMB 30.3 billion, a year-over-year increase of 52%, driven by the acquisition of an overseas company which contributed approximately RMB 7.8 billion to the profit [1][4]. - The report anticipates a recovery in the amino acid market, supported by increased penetration in the aquaculture sector and a favorable demand outlook due to reduced soybean meal usage [1][3]. Summary by Sections Financial Performance - For the first three quarters of 2025, the feed amino acids revenue was RMB 8.19 billion, down 2% year-over-year, while lysine sales increased despite price declines. The average prices for lysine and threonine were RMB 8.5/kg and RMB 10.0/kg, reflecting year-over-year decreases of 16% and 5% respectively [2]. - The overall gross margin improved by 2.4 percentage points to 21.3% due to lower raw material costs [2]. Market Outlook - The prices for key products such as lysine and threonine are currently at low levels, but demand is expected to recover as aquaculture penetration increases and consumer demand rebounds [3]. - The company is expanding its product line through acquisitions, which will enhance its high-value pharmaceutical amino acid offerings and support its international expansion strategy [3]. Profit Forecast and Valuation - The net profit forecast for 2025 has been adjusted down to RMB 3.54 billion, a 3% decrease from previous estimates, while maintaining projections of approximately RMB 3.6 billion and RMB 3.8 billion for 2026 and 2027 respectively [4]. - The expected earnings per share (EPS) for 2025 is RMB 1.26, with a projected price-to-earnings (P/E) ratio of 11x for 2025 [4][8].

Company Update - MeiHua Bio's Singapore subsidiary signed a share and asset purchase agreement with Kirin Holdings' wholly-owned subsidiary, Kyowa Hakko Bio Co., Ltd., to acquire its food amino acids, pharmaceutical amino acids, and human milk oligosaccharides (HMO) business for 10.5 billion JPY (approximately 500 million RMB) in cash [1] - The transaction price is approximately 16.8 billion JPY (about 833 million RMB) based on the cash retention of the target assets and working capital adjustments as of the closing date, with the asset transfer completed by July 2025 [1] Commentary - The acquisition of high-quality assets at a low cost and its completion accelerates MeiHua Bio's global expansion [2] - The asset valuation report indicates that the total equity value of the acquired businesses is estimated at 1.626 billion RMB, making the transaction price of 833 million RMB particularly cost-effective [2] - The company expects to recognize an increase in non-operating income of approximately 780 million RMB in the 2025 consolidated profit statement, enhancing certainty in overseas expansion [2] - The acquisition expands the amino acid product pipeline and extends into the high-value pharmaceutical-grade amino acid market, while also increasing production entities in Thailand and North America, thereby enhancing global competitiveness [2] Profit Forecast and Valuation - Considering the non-operating income from the transaction but a decline in amino acid market conditions, the profit forecast for 2025 is raised by 7% to 3.37 billion RMB, while the 2026 profit forecast remains unchanged at 3.2 billion RMB [3] - The current stock price corresponds to 8.9 times the 2025 earnings and 9.3 times the 2026 earnings [3] - The target price remains at 13.7 RMB, corresponding to 11.4/12.0 times the earnings for 2025/26, with a potential upside of 28%, maintaining an outperform rating in the industry [3]

Overview - Tryptophan is an essential amino acid that cannot be synthesized by the human body and must be obtained through food [2][4] - The market demand for tryptophan has rapidly increased due to the development of the livestock industry and the "reduction of soybean meal substitution" policy [4][9] - In 2024, the demand for tryptophan in China is projected to reach 23,800 tons, with a market size of 1.309 billion yuan [4][9] Market Policy - The Chinese government has issued several policies to support the development of the amino acid industry, including the "14th Five-Year Plan" and various guidelines for the pharmaceutical and feed industries [4][5] Industry Chain - The upstream of the tryptophan industry includes suppliers of raw materials like corn and molasses, while the midstream involves the production of tryptophan, and the downstream encompasses applications in feed, pharmaceuticals, health products, and food [6][7] Current Development - The feed sector accounts for over 70% of the demand for tryptophan in China, with industrial feed production expected to reach 158.5 million tons in the first half of 2025, a year-on-year increase of 7.7% [9][10] - The increasing focus on health foods has led to a rise in the use of tryptophan as a nutritional supplement for improving sleep and emotional balance [4][9] Competitive Landscape - The market concentration of tryptophan has increased, with international companies like Ajinomoto and CJ Cheiljedang holding significant market shares, while domestic companies such as Ningxia Yipin Biotechnology and Anhui Huaheng Biological Technology are gaining ground through innovation and resource advantages [10][11] Key Players - Fujian Group is a major player in the tryptophan market, with projected revenues of 27.76 billion yuan and a gross profit of 5.057 billion yuan in 2024 [12] - Anhui Huaheng Biological Technology focuses on synthetic biology and expects revenues of 2.178 billion yuan in 2024, with amino acid products contributing 69.28% of total revenue [12][13] Future Trends - The production of tryptophan is primarily through microbial fermentation, with future advancements expected in genetic engineering to enhance production efficiency and product purity [14] - There is a growing emphasis on green production processes to reduce costs and environmental impact, aligning with stricter environmental regulations [14]

Core Viewpoint - The company reported a mixed performance in its 2025 semi-annual report, with a slight decline in revenue but a significant increase in net profit compared to the previous year [1] Financial Performance - In the first half of 2025, the company achieved revenue of 12.28 billion yuan, a year-on-year decrease of 2.9%, while the net profit attributable to shareholders was 1.77 billion yuan, an increase of 20.0% [1] - For the second quarter, revenue was 6.01 billion yuan, down 2.3% year-on-year and 4.1% quarter-on-quarter, with net profit of 750 million yuan, reflecting a year-on-year increase of 3.8% but a quarter-on-quarter decrease of 26.5% [1] - The gross margin for the first half of 2025 was 23.2%, up 3.7 percentage points year-on-year, while the second quarter gross margin was 21.7%, showing a year-on-year increase of 2.0% but a quarter-on-quarter decrease of 2.9 percentage points [1] Product Segment Performance - The flavoring agent segment generated revenue of 3.57 billion yuan, down 8.1% year-on-year, accounting for 29% of total revenue; the feed amino acid segment saw revenue of 5.66 billion yuan, up 3.4% year-on-year, making up 46% of total revenue [2] - The pharmaceutical amino acid segment reported revenue of 250 million yuan, down 1.0% year-on-year, while the raw material by-products segment generated 1.89 billion yuan, down 1.2% year-on-year, and the other products segment saw revenue of 920 million yuan, down 18.7% year-on-year [2] - The mixed performance across segments was attributed to a significant decline in sales prices for flavoring products despite increased production capacity, while the feed amino acid segment benefited from a 98% increase in lysine sales volume [2] Price and Cost Dynamics - In the second quarter, amino acid product prices declined, with lysine's market price dropping to 8.3 yuan/kg, down 16.0% quarter-on-quarter; threonine's price was 10.2 yuan/kg, down 3.6%; and valine's price was 13.7 yuan/kg, down 8.6% [3] - Corn prices increased due to faster grain sales and lower inventory levels, with the second quarter market price reaching 2,348 yuan/ton, up 6.9% quarter-on-quarter, impacting the company's profitability as corn constitutes over 50% of raw material costs [3] Strategic Developments - The company is accelerating its overseas strategy by acquiring Kyowa Hakko Bio's food amino acids, pharmaceutical amino acids, and oligosaccharides business for 10.5 billion yen, with the transaction expected to complete by July 2025 [4] - This acquisition will enhance the company's global intellectual property in amino acid fermentation, expand its product pipeline, and establish new production bases in Shanghai, Thailand, and North America, thereby improving its competitive edge and global presence [4] Profit Forecast and Valuation - The company forecasts revenues of 26.87 billion yuan, 29.49 billion yuan, and 31.32 billion yuan for 2025-2027, representing year-on-year growth of 7.2%, 9.8%, and 6.2% respectively; net profits are expected to be 3.20 billion yuan, 3.67 billion yuan, and 4.00 billion yuan, with year-on-year growth of 16.9%, 14.7%, and 8.8% [4]

Core Viewpoint - Meihua Biotech reported a slight decline in revenue but a significant increase in net profit, indicating effective cost management and product performance Group 1: Financial Performance - The company achieved operating revenue of 12.28 billion, a year-on-year decrease of 2.87% [1] - The net profit attributable to the company, excluding non-recurring items, was 1.628 billion, reflecting a year-on-year growth of 24.98% [1] - Key products such as monosodium glutamate, 98% lysine, and feed-grade isoleucine saw sales growth, while 70% lysine experienced both volume and price increases, contributing to higher gross margins [1] Group 2: Global Expansion - Meihua Biotech has advanced its global operations, completing a cross-border acquisition in July, marking a shift from strategic planning to actual operations [2] - The acquisition adds new amino acid products and production bases in Shanghai, Thailand, and North America, enhancing the company's capabilities in high-value downstream products [2] - The company aims to increase its market share in high-quality overseas markets for pharmaceutical-grade amino acids and improve profitability for food-grade amino acids through production efficiency [2] Group 3: Competitive Positioning - The company successfully reduced the EU anti-dumping duty rate on lysine from an initial 84.8% to 47.7%, strengthening its competitive position in international markets [3] Group 4: Capacity Upgrade and Digital Transformation - Meihua Biotech invested 1.087 billion in project expenditures, with the Tongliao monosodium glutamate capacity upgrade project achieving full production [4] - The company is implementing a Manufacturing Execution System (MES) to enhance production management, with significant improvements in operational efficiency reflected in inventory and accounts receivable turnover days [4] - Continued investment in R&D focuses on core technology platform development and strain optimization, with a pilot research platform established in Jilin for amino acids and polysaccharides [4]